DDReg pharma

Quailty Driven by Passion

Regulatory

Home » Blogs » Regulatory » Page 14
Pharmaceutical

WHO Pre-qualification pathway: advancing access to vaccines

Introduction Malaria is one of the biggest and most pressing tropical and infectious diseases that pose a significant  threat to public health- particularly children. In 2019, a study analysis found that malaria caused 643,000 deaths globally with children <5 years of age living in Africa and exhibiting the highest disease burden [1]. According to the […]

WHO Pre-qualification pathway: advancing access to vaccines Read More »

Pharmacovigilance

DARWIN EU – Generating Real-World Evidence to Support Regulatory Decisions

The European Medicines Agency (EMA) has created a sustainable network called DARWIN EU, which aims to generate real-world evidence to support regulatory decision-making in the European Union. This coordination centre network uses data analysis techniques and real-world interrogation methods to extract information and insights from various data sources, including structured and unstructured sources. Its main

DARWIN EU – Generating Real-World Evidence to Support Regulatory Decisions Read More »

Oncology Therapeutics

Benefits of randomized control trials in accelerated approvals for oncology therapeutics

In 1992 the US FDA established the accelerated approval pathway for drug development as treatment options for serious or life-threatening conditions like cancer based on the effect the drug has on surrogate measures or an intermediate clinical end-point that could predict the real endpoint. However, these investigational drugs are subjected to post-approval confirmatory studies which

Benefits of randomized control trials in accelerated approvals for oncology therapeutics Read More »

Clinical Evaluation Report

Medical Devices – Considerations for preparing a Clinical Evaluation Report (CER)

Overview Medical Device manufacturers must demonstrate the safety, efficacy, and quality, of the product and that it functions as intended without endangering the user or patient. The European Medicines Agency (EMA) mandated a clinical evaluation report (CER) that is required to obtain a CE marking for devices that are to be marketed within the European

Medical Devices – Considerations for preparing a Clinical Evaluation Report (CER) Read More »

EU Regulatory Strategic Goals For Human Medicines

EU regulatory strategic goals for human medicines

The European regulatory system constitutes a network of pharmaceutical regulators from the European Economic Area (EEA), the European Medicines Agency (EMA), and the European Commission (EC). In addition to ensure that patients have timely access to safe, efficacious and high quality medicines, it is responsible for establishing a regulatory environment that keeps up with innovation.

EU regulatory strategic goals for human medicines Read More »

Drug Safety

Social & Digital Media Sources in Drug Safety

A crucial part of pharmacovigilance (PV) and post-market drug safety surveillance are unsolicited adverse event (AE) reports from various stakeholders including patients, pharmaceutical organizations, and healthcare professionals. These are spontaneous reports and serve as important sources of safety information for a product. Regulatory agencies rely on spontaneous reports for post-market safety surveillance from which they

Social & Digital Media Sources in Drug Safety Read More »

Analytical Assessment Techniques

An overview on the analytical assessment techniques for biosimilar development

Successful biosimilar approval is determined by how well biosimilarity can be demonstrated between the proposed product and its innovator product. An analytical biosimilarity study provides the technical data that would confirm the similarity of critical quality attributes (CQAs) of the proposed product to its innovator in terms of safety, efficacy, and potency. This constitutes comprehensive

An overview on the analytical assessment techniques for biosimilar development Read More »

biosimilar regulatory pathway in EU and USA

Differences in the regulatory pathways for biosimilar development: EU vs USA

Regulations surrounding biosimilar development are based on how well the similarity between the proposed molecule and the reference product (RP) can be demonstrated. Indeed, there is a need for increased access to cost-effective treatment for various conditions, which drives biosimilar development. Regulatory agencies such as the US Food and Drug Administration (FDA) and the European

Differences in the regulatory pathways for biosimilar development: EU vs USA Read More »

US FDA Guidance in ANDA applicants for Active ingredients

US FDA draft guidance: Sameness Evaluations in an ANDA for active ingredients

As per FDA’s pre-requisites for Abbreviated New Drug Application (ANDA) filings, applicants should be able to demonstrate their product’s sameness or similarity to its innovator product or Reference Product (RP). All the data generated by applicants on generic versions should be equivalent or the same as that for reference-listed drugs (RLD). The CDER recently issued

US FDA draft guidance: Sameness Evaluations in an ANDA for active ingredients Read More »

biosimilar products guidance for Licensing in Uk Mhra

A summary of the “Guidance on the licensing of biosimilar products”- UK MHRA

The pharmaceutical regulatory landscape in the UK has experienced many changes since Brexit. Several guidelines have been updated for more UK-specific pharmaceutical product regulation. Among these includes the ‘Guidance on the licensing of biosimilar products’ that was first published on the 6th of May 2021 with the aim to outline clear requirements for biosimilar product

A summary of the “Guidance on the licensing of biosimilar products”- UK MHRA Read More »